Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TRD2
- Development stage
- Preclinical
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
TRD2 is a novel proteolysis targeting chimera (PROTAC) designed to degrade RAD51 recombinase. It has demonstrated the ability to reduce RAD51 protein levels and inhibit cell proliferation in multiple myeloma (MM) cell lines, including those resistant to existing treatments like lenalidomide and dexamethasone. In preclinical in vivo studies, TRD2 showed synergistic effects with the chemotherapy drug cisplatin in inhibiting tumor growth in lenalidomide-resistant MM xenograft models without significant toxicity. By targeting RAD51, TRD2 aims to enhance the efficacy of DNA-damaging treatments and overcome drug resistance in MM.
- Other names
- Targeted RAD51 degradation 2
02
Targets
CRBN (Cereblon)RAD51 (RAD51 Recombinase)
Beyond the preview
Go deeper on TRD2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TRD2.